A 2026 informational release covering what the Leanzene BHB + apple cider vinegar gummy label discloses, where published ingredient research supports category-level claims at studied dosages, how ...

Kevin Richardson, CEO, Telix Precision Medicine, added, “The FDA’s acceptance of our NDA resubmission is an important milestone for Telix. We appreciate the FDA’s constructive engagement and look ...

A 2026 informational report examining Vita Smart Cup Massager's marketing claims, device specifications not disclosed on the product page, cupping and red light research context, return policy fine ...

A live webcast of the presentation will be available on the “Investors” page under the “Events” section of the Company’s website at https://ir.lbpharma.us/investors/events/, where a replay of the ...

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for ...

While the financial statements in the Company’s 2025 Annual Report reflect a year focused primarily on corporate restructuring and building the Company’s acquisition platform, management believes the ...

A live and archived webcast of the event will be available on the “Investors” section of the Certara website at About Certara Certara accelerates medicines using biosimulation software, technology ...

About NARCAN® Nasal Spray NARCAN ® Nasal Spray is a pure opioid antagonist indicated for emergency use to reverse known or suspected opioid overdose, as manifested by respiratory and/or severe central ...

Not for distribution to U.S. news wire services or dissemination in the United States.

A veteran architect of Gemini’s Asia Pacific expansion, Ms. Gani joins to lead institutional buildout as Solana Company executes on its strategy to drive yield expansion, enhance revenue generation, ...

Dental Care of Stamford, a trusted dental practice serving Fairfield County, has published a comprehensive patient resource addressing one of the most persistent challenges in cosmetic dentistry: not ...

EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced ...